In 687 analysed adults with pulmonary arterial hypertension on background therapy, ralinepag vs placebo cut first clinical worsening (18% vs 36%; HR 0·45, 95% CI 0·33–0·62), but more stopped for adverse events (19% vs 3%).
RCTn = 728
McLaughlin et al. Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study